Since capillarization of LSECs matters in the fibrotic process in a variety of liver diseases, adding the circulating level of A-FABP is positively correlated with the degree of fibrosis in patients with NASH (Furuta et al., 2020), A-FABP is expected to serve as a potent target for inhibiting the fibrogenic pathological process of liver diseases (Wu et al., 2021). The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatohepatitis.